Stanley-Laman Group’s Amicus Therapeutics FOLD Stock Holding History

Stanley-Laman Group’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-21,082	Closed	-$263K	–	271
2019 Q2	$263K	Buy	+21,082	New	+$268K	0.06%	239

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Stanley-Laman Group's FOLD Position: Q3 2019 in Review

Stanley-Laman Group sold out of Amicus Therapeutics (FOLD) in Q3 2019, closing a stake of 21,082 shares — an estimated $263K sold.

Stanley-Laman Group first reported a position in FOLD in Q2 2019 and held it in 1 quarter. The position peaked at $263K in Q2 2019. 204 funds tracked by Wall St. Rank hold FOLD as of Q3 2019.

Stanley-Laman Group reported no remaining Amicus Therapeutics position as of Q3 2019 after selling out during the quarter.
Stanley-Laman Group sold 21,082 Amicus Therapeutics shares in Q3 2019, an estimated $263K.
Stanley-Laman Group first reported a position in Amicus Therapeutics in Q2 2019 and held it in 1 quarter.
Stanley-Laman Group's Amicus Therapeutics position peaked at $263K in Q2 2019.
204 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2019.

Based on Stanley-Laman Group's 13F filing for Q3 2019, filed 8 Nov 2019.